Current Clinical Needs
In the majority of the patients with myeloproliferative neoplasm-associated myelofibrosis (MPN-MF), the disease interferes with the quality of life and social activities. A great proportion of patients suffer of general symptoms, such as fatigue, constitutional symptoms, or pruritus, that reflect the biological activity of the underlying disease. The greatest impact on the patients’ well-being is offered by severe anemia and progressive splenomegaly, and the therapy of these manifestations represents a major medical needs. Some of the disease complications, such as hemorrhagic or thrombotic events and infections, need treatments that are not specific for MPN-MF. On the contrary, treatment of extramedullary nonhepatosplenic hematopoiesis, treatment of pulmonary or portal hypertension, and therapy for the accelerated phase and of blast transformation of the disease are MPN-MF-specific medical needs.
KeywordsPulmonary Hypertension Portal Hypertension Iron Overload Transjugular Intrahepatic Portosystemic Shunt National Comprehensive Cancer Network
- Ishii T, Wang J, Zhang W et al (2009) Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 1133:5942–5950Google Scholar
- Mesa RA, Kantarjian H, Tefferi A et al (2011b) Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. doi: 10.1002/cncr.26129
- Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haemopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
- Vannucchi AM, Guglielmelli P, Lupo L et al. (2010) A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results. Blood (ASH Annual Meeting Abstracts) 116:314Google Scholar